This site is intended for healthcare professionals
CSU Learning Zone
Declaration of sponsorship Novartis AG and J. Uriach y Compañía S.A

ACAAI Virtual 2020

Declaration of sponsorship Novartis AG and J. Uriach y Compañía S.A
Read time: 5 mins
Last updated:24th Nov 2020
Published:13th Nov 2020
Explore this section for the latest updates in chronic spontaneous urticaria treatment and management from the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. New blogs to be added daily so stay tuned for updates.

These blogs have been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content.

Don’t have time to attend ACAAI this year? Don’t worry! Below you’ll find some of the sessions, ePosters, and abstracts we’ll be highlighting in our upcoming daily blogs, so that you can stay up to date with the latest research being presented this year.

The American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting attracts thousands of scientists, specialists and healthcare professionals from around the world to explore the latest insights and innovations in a wide range of areas, including chronic spontaneous urticaria (CSU).

Register free for full access to medthority.com

Explore the results of two studies assessing the efficacy and achievement of symptom control of ligelizumab compared to omalizumab in patients with chronic spontaneous urticaria in the sessions below from ACAAI 2020.

Ligelizumab is a next generation high-affinity monoclonal anti-IgE antibody that has recently been developed to potentially overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody omalizumab1.

Register free for full access to medthority.com

How do we optimise the treatment of chronic spontaneous urticaria and what treatment options remain when omalizumab fails? Find out the latest strategies for managing refractory urticaria in the sessions below from ACAAI 2020.

The current mainstay of therapy for chronic spontaneous urticaria are second-generation antihistamines. However, in patients who do not respond to these agents, a variety of other medications can be used.

Register free for full access to medthority.com

What has the latest research in biomarkers and treatments for chronic spontaneous urticaria found? Find out in the clinically-focused literature review below from ACAAI 2020.

For the final day of the American College of Allergy, Asthma & Immunology (ACAAI) 2020 Annual Scientific Meeting, we’ll be sharing the latest updates in chronic spontaneous urticaria (CSU) research with a clinically-focused literature review and an emphasis on clinical relevance.

Register free for full access to medthority.com

Did you miss ACAAI 2020? Don’t worry, find out about the best sessions and presentations that came up over the three days in our brief recap below.

The presentations on chronic spontaneous urticaria (CSU) were a fascinating hidden gem of the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2020.

Register free for full access to medthority.com

We hope you enjoyed our brief overview of the unmissable chronic spontaneous urticaria presentations that came up at ACAAI 2020. Now that it’s over, why not have a go at our from ACAAI 2020?

Register free for full access to medthority.com

We catch up with Professor Marcus Maurer to get his thoughts on the 2020 ACAAI Annual Scientific Meeting and find out what new developments we can expect to see in the world of urticaria over the coming months.

Register free for full access to medthority.com

Welcome: